OBJECTIVES: To describe quality of life (QoL) in an ANCA-associated vasculitis (AAV) cohort and make comparisons with a general population sample. In addition, we aimed to take preliminary steps to identify potential disease and psycho-social factors which may determine QoL impairment. METHODS: A population-based case-control study was designed. All AAV patients resident in Grampian, Scotland, were invited to participate as cases. Controls were identified from a random sample of persons registered with four local general practices. Participants completed a questionnaire comprising validated generic and symptom-specific tools in the assessment of QoL. In addition, all cases were clinically assessed and putative disease factors recorded. Cases and controls were compared and, in addition, disease and psycho-social associations were explored for identified QoL impairments. RESULTS: In total, 74/90 (82%) cases and 781/2000 (39%) controls participated. Cases reported a significant impairment in physical health (P < 0.0001), but not mental health (P = 0.85), compared with controls, as measured by Short Form-8 (SF-8). Following adjustment for age and sex, persons with AAV were more than twice as likely to report mild/moderate fatigue [odds ratio (OR) 2.0; 95% CI 1.1, 3.8] or severe fatigue (OR 2.5; 95% CI 1.4, 4.5) compared with controls. Furthermore, among cases, fatigue was found to be strongly associated with impaired physical health (P < 0.0001), while disease factors such as disease activity and damage were not (P = 0.60 and 0.27, respectively). CONCLUSIONS: Patients with AAV report impaired physical but not mental health. Specifically, fatigue is a principal complaint and appears to be a major determinant of impaired QoL.
OBJECTIVES: To describe quality of life (QoL) in an ANCA-associated vasculitis (AAV) cohort and make comparisons with a general population sample. In addition, we aimed to take preliminary steps to identify potential disease and psycho-social factors which may determine QoL impairment. METHODS: A population-based case-control study was designed. All AAVpatients resident in Grampian, Scotland, were invited to participate as cases. Controls were identified from a random sample of persons registered with four local general practices. Participants completed a questionnaire comprising validated generic and symptom-specific tools in the assessment of QoL. In addition, all cases were clinically assessed and putative disease factors recorded. Cases and controls were compared and, in addition, disease and psycho-social associations were explored for identified QoL impairments. RESULTS: In total, 74/90 (82%) cases and 781/2000 (39%) controls participated. Cases reported a significant impairment in physical health (P < 0.0001), but not mental health (P = 0.85), compared with controls, as measured by Short Form-8 (SF-8). Following adjustment for age and sex, persons with AAV were more than twice as likely to report mild/moderate fatigue [odds ratio (OR) 2.0; 95% CI 1.1, 3.8] or severe fatigue (OR 2.5; 95% CI 1.4, 4.5) compared with controls. Furthermore, among cases, fatigue was found to be strongly associated with impaired physical health (P < 0.0001), while disease factors such as disease activity and damage were not (P = 0.60 and 0.27, respectively). CONCLUSIONS:Patients with AAV report impaired physical but not mental health. Specifically, fatigue is a principal complaint and appears to be a major determinant of impaired QoL.
Authors: Anthony D Booth; Mike K Almond; Aine Burns; Peter Ellis; Gill Gaskin; Guy H Neild; Martin Plaisance; Charles D Pusey; David R W Jayne Journal: Am J Kidney Dis Date: 2003-04 Impact factor: 8.860
Authors: Erin E Michalak; Greg Murray; Clare Wilkinson; Chris Dowrick; Lourdes Lasa; Ville Lehtinen; Odd Steffen Dalgard; Jose Luis Ayuso-Mateos; Jose Luis Vázquez-Barquero; Patricia Casey Journal: Psychiatry Res Date: 2004-11-30 Impact factor: 3.222
Authors: Peter C Grayson; Naomi A Amudala; Carol A McAlear; Renée L Leduc; Denise Shereff; Rachel Richesson; Liana Fraenkel; Peter A Merkel Journal: J Rheumatol Date: 2014-03-15 Impact factor: 4.666
Authors: Michael Walsh; Chetan Mukhtyar; Alfred Mahr; Karen Herlyn; Raashid Luqmani; Peter A Merkel; David R W Jayne Journal: Arthritis Care Res (Hoboken) Date: 2011-07 Impact factor: 4.794
Authors: Gunnar Tomasson; John T Farrar; David Cuthbertson; Carol A McAlear; Susan Ashdown; Peter F Cronholm; Jill Dawson; Don Gebhart; Georgia Lanier; Raashid A Luqmani; Nataliya Milman; Jacqueline Peck; Joanna C Robson; Judy A Shea; Simon Carette; Nader Khalidi; Curry L Koening; Carol A Langford; Paul A Monach; Larry Moreland; Christian Pagnoux; Ulrich Specks; Antoine G Sreih; Steven R Ytterberg; Peter A Merkel Journal: J Rheumatol Date: 2019-03-01 Impact factor: 4.666
Authors: Delesha M Carpenter; Amy E Meador; Emily A Elstad; Susan L Hogan; Robert F DeVellis Journal: Clin Exp Rheumatol Date: 2012-05-10 Impact factor: 4.473
Authors: Philipp Moog; O Eren; S Kossegg; K Valda; A Straube; M Grünke; H Schulze-Koops; M Witt Journal: Clin Auton Res Date: 2017-09-01 Impact factor: 4.435
Authors: Joanna C Robson; Nataliya Milman; Gunnar Tomasson; Jill Dawson; Peter F Cronholm; Katherine Kellom; Judy Shea; Susan Ashdown; Maarten Boers; Annelies Boonen; George C Casey; John T Farrar; Don Gebhart; Jeffrey Krischer; Georgia Lanier; Carol A McAlear; Jacqueline Peck; Antoine G Sreih; Peter S Tugwell; Raashid A Luqmani; Peter A Merkel Journal: J Rheumatol Date: 2015-09-01 Impact factor: 4.666
Authors: Peter C Grayson; Naomi A Amudala; Carol A Mcalear; Renée L Leduc; Denise Shereff; Rachel Richesson; Liana Fraenkel; Peter A Merkel Journal: Arthritis Care Res (Hoboken) Date: 2013-11 Impact factor: 4.794
Authors: Vivek Nagaraja; Constance Mara; Puja P Khanna; Rajaie Namas; Amber Young; David A Fox; Timothy Laing; William J McCune; Carol Dodge; Debra Rizzo; Maha Almackenzie; Dinesh Khanna Journal: Qual Life Res Date: 2017-10-05 Impact factor: 4.147